Blood Journal
Leading the way in experimental and clinical research in hematology

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

  1. Hartmut Döhner1,
  2. Elihu H. Estey2,
  3. Sergio Amadori3,
  4. Frederick R. Appelbaum4,
  5. Thomas Büchner5,
  6. Alan K. Burnett6,
  7. Hervé Dombret7,
  8. Pierre Fenaux8,
  9. David Grimwade9,
  10. Richard A. Larson10,
  11. Francesco Lo-Coco11,
  12. Tomoki Naoe12,
  13. Dietger Niederwieser13,
  14. Gert J. Ossenkoppele14,
  15. Miguel A. Sanz15,
  16. Jorge Sierra16,
  17. Martin S. Tallman17,
  18. Bob Löwenberg18, and
  19. Clara D. Bloomfield19
  1. 1Department of Internal Medicine III, University of Ulm, Ulm, Germany;
  2. 2Seattle Cancer Center Alliance, WA;
  3. 3Department of Hematology, Tor Vergata University Hospital, Rome, Italy;
  4. 4Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;
  5. 5Department of Hematology/Oncology, University of Münster, Münster, Germany;
  6. 6Department of Haematology, University of Wales College of Medicine, Cardiff, United Kingdom;
  7. 7Institut Universitaire d‘Hématologie Hôpital St. Louis, Assistance Publique-Hôpitaux de Paris, Paris, France;
  8. 8Service d'Hématologie Clinique, Hôpital Avicenne, Bobigny, France;
  9. 9Department of Medical and Molecular Genetics, Guy's King's and St. Thomas' School of Medicine, London, United Kingdom;
  10. 10Department of Medicine and Cancer Research Center, University of Chicago, IL;
  11. 11Department of Biopathology, University Tor Vergata and Santa Lucia Foundation at Centro Europeo per la Ricerca sul Cervello, Rome, Italy;
  12. 12Department of Hematology, Nagoya University Hospital, Showa-ku, Japan;
  13. 13Department of Hematology, Oncology and Hemostasis, University of Leipzig, Leipzig, Germany;
  14. 14Department of Haematology, VU University Medical Center, Amsterdam, The Netherlands;
  15. 15Hematology and Bone Marrow Transplant Unit, University Hospital La Fe, Valencia, Spain;
  16. 16Clinical Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain;
  17. 17Division of Hematology-Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL;
  18. 18Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands; and
  19. 19The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital, Columbus


In 2003, an international working group last reported on recommendations for diagnosis, response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that time, considerable progress has been made in elucidating the molecular pathogenesis of the disease that has resulted in the identification of new diagnostic and prognostic markers. Furthermore, therapies are now being developed that target disease-associated molecular defects. Recent developments prompted an international expert panel to provide updated evidence- and expert opinion–based recommendations for the diagnosis and management of AML, that contain both minimal requirements for general practice as well as standards for clinical trials. A new standardized reporting system for correlation of cytogenetic and molecular genetic data with clinical data is proposed.

  • Submitted July 28, 2009.
  • Accepted September 30, 2009.
View Full Text